PCM
MRTX

Prelude Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Prelude Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Upgrade to unlock
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
2023
Q4 		$2.4M Buy
2023
Q3 		$208K Buy
2020
Q4 		– Sell
2020
Q3 		$167K Buy
2020
Q1 		– Sell
2019
Q4 		$16K Sell
2019
Q3 		$233K Buy
2018
Q4 		– Sell
2018
Q3 		$139K Buy
2016
Q4 		– Sell
2016
Q3 		$22K Buy